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Abstract
Immunochemical fecal occult blood tests (iFOBTs) are increasingly used for colorectal cancer (CRC) screening. In our
preceding observational study, sensitivity for detecting advanced colorectal neoplasms by iFOBT was 70.8% among
users of low-dose acetylsalicylic acid compared with 35.9% among non-users (p = 0.001), whereas there were only
very small differences in specificity. In receiver operating characteristics (ROC) analyses, the area under the curve
(AUC) was much higher for acetylsalicylic acid users than for non-users, with particularly strong differences in men
(0.87 versus 0.68, p = 0.003). These findings suggested that use of acetylsalicylic acid before conduct of iFOBT might
be a promising approach to improve non-invasive screening for CRC.
Methods/design: In this randomized, double-blind, placebo-controlled trial, the diagnostic performance of two iFOBTs
for detecting advanced colorectal neoplasms after a single low-dose of acetylsalicylic acid (300 mg) compared to
placebo is evaluated. Acetylsalicylic acid or placebo is administered at least 5 days before a planned, study-
independent colonoscopic screening in 2400 participants aged 40 to 80 years. Stool samples are obtained before and
on three different days after the single dose of acetylsalicylic acid or placebo. In addition, optional blood samples are
taken for future biomarker analyses. The diagnostic performance of the iFOBTs will be compared to the results of the
colonoscopy as a gold standard for the diagnosis of colorectal neoplasms. Additionally, gender-specific performance of
the tests and gain in diagnostic performance by test application on multiple days will be evaluated.
Discussion: If the findings from our preceding observational study will be confirmed in this large trial, the proposed
low-risk, inexpensive intervention would considerably improve the diagnostic accuracy of iFOBTs and thus lead to
enhanced early detection of colorectal neoplasms. Thus, the results of this trial may have a large public health impact.
Trial registration: This trial was registered before recruitment of the participants in www.clinicaltrialsregister.eu on the
30th of May 2012: EudraCT No.: 2011–005603-32 and in www.drks.de on 13th of March 2012: German Clinical Trials
Register DRKS-ID: DRKS00003252.
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Background
Colorectal cancer (CRC) is the third most common can-
cer and the fourth most common cancer cause of death
globally, with more than 1.3 million new cases and more
than 700,000 deaths annually [1]. In Germany, there are
over 60,000 new cases and around 25,000 deaths due to
CRC per year [2]. The commonly slow progression from
detectable and fully curable precursors (adenomas) to
still-curable early-stage CRC to advanced CRC provides
promising perspectives for prevention and early detec-
tion by screening.
Randomized studies have demonstrated that CRC inci-
dence and CRC-associated mortality can be reduced by
20–30% through annual or biennial screening with fecal
occult blood tests (FOBTs) [3–5], despite the low sensitiv-
ity for detection of colorectal adenomas of conventional
(guaiac based) FOBTs. Substantially higher sensitivity for
detection of colorectal adenomas can be achieved with
newer, immunochemical FOBTs (iFOBTs), which are in-
creasingly recommended and employed for non-invasive
CRC screening. Although iFOBTs detect approximately
four out of five CRCs [6], the sensitivity for detecting ad-
vanced adenomas, the precursors of most CRCs, still re-
mains far below 50% at cut points yielding 90–95%
specificity required for population-based screening. Thus,
there is an unmet medical need for easy-to-implement
screening methods for detection of high-risk colorectal
adenomas in addition to CRC.
In our preceding prospective screening study conducted
among 1979 participants of screening colonoscopy in
Germany, the sensitivity for detecting advanced colorectal
neoplasms (i.e. either CRC or advanced adenoma) by
iFOBT was 70.8% among users of low-dose acetylsalicylic
acid compared with 35.9% among non-users (p = 0.001),
whereas there were only very small differences in specifi-
city (85.7% for users compared with 89.2 to 91.1% for
non-users) [7]. In receiver operating characteristics (ROC)
analyses, the area under the curve (AUC) was much
higher among users than among non-users, with differ-
ences being particularly pronounced among men (0.87
versus 0.68, p = 0.003). This suggests that use of acetylsali-
cylic acid prior to conduct of iFOBT might be a particu-
larly promising approach for enhancing non-invasive
screening for CRC. It is hypothesized that the underlying
mechanism could be an enhanced tendency of (micro-)-
bleeding of colorectal neoplasms.
Objectives
The main objective of this trial is to evaluate the diag-
nostic performance (sensitivity, specificity, positive and
negative predictive values, likelihood ratios, and AUC
of two iFOBTs for detecting advanced colorectal neo-
plasms after a single dose of acetylsalicylic acid as com-
pared to placebo.
Secondary objectives are: 1) To study gender-specific
performance of the two iFOBTs and the possible gain in
diagnostic performance by stool sampling on multiple
days; 2) To study the safety of single-dose acetylsalicylic
acid in the selected population; 3) To collect blood sam-
ples for additional biomarker analyses (optional).
Methods/Design
Study design
This trial is designed as a randomized, double-blind,
placebo-controlled, phase III multicenter trial (German
title: ‘Mit ASS Darmtumore früher erkennen’, acronym
ASTER).
Screening
In total, 2400 eligible participants aged 40 to 80 years and
with no recent use of acetylsalicylic acid are recruited
when visiting one of the collaborating gastroenterology
private practices or hospitals (hereinafter referred to as
‘study centers’) for an informative appointment, which is
routinely scheduled a few weeks before colonoscopy. The
study flow of the trial is illustrated in Fig. 1. The exact
schedule can be found in Table 1. In addition to partici-
pants scheduled for a screening colonoscopy, patients vis-
iting the study centers for a diagnostic colonoscopy
meeting the inclusion criteria are also asked to participate.
Thus, the colonoscopy procedure is planned beforehand
and conducted independently from our trial.
During the first appointment (day of Screening), partici-
pants are informed about the trial, receive the printed
study information, and have the opportunity to ask ques-
tions. A detailed medical and drug history is taken and in-
clusion and exclusion criteria are checked (see the full list
of inclusion and exclusion criteria for details in Appendix).
Women who are not postmenopausal must have a nega-
tive pregnancy test before signing consent. If all inclusion
criteria are met, no exclusion criteria are present, and the
patient consents to the blood sampling, four extra tubes
of blood (2 EDTA tubes and 2 serum tubes) are taken for
analysis of additional biomarkers (optional). In addition,
patients receive four iFOBT kits for each of two different
iFOBTs (FOBGold®Tube Screen, an internationally widely
used quantitative iFOBT [8, 9], as well as the FD Hb/Hp
Complex quick test, a qualitative chromatographic
test from Frost Diagnostika; hence, eight stool kits in total
are dispensed along with instructions on when and how to
use them and including a device that is hung in the toilet
and aids in easy collection of the stool samples.
Study medication
Participants are randomized to receive either a single dose
of 300 mg acetylsalicylic acid (without enteric coating,
Ratiopharm GmbH) or placebo (containing cellulose, lac-
tose and magnesium stearate; Winthrop Arzneimittel
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GmbH); thereby, a unique participant number is gener-
ated and documented on the day of screening in the par-
ticipants’ log.
Both, participants and their physicians are blinded
with respect to the study medication.
Stool collection
Participants are asked to collect a baseline stool sample
before taking the study medication. If the participant
cannot collect a stool sample at baseline (e.g. due to
constipation), this stool sample is skipped and the study
medication is taken without a baseline stool sample. Fur-
ther stool samples are collected from day 2 onwards on
3 different, preferably consecutive days (day 2, 3, and 4).
If stool collection on these days is not possible because
of constipation or other reasons, stool collection may be
postponed to the subsequent day. Participants are still
eligible for inclusion in the analysis if they only provide
two stool samples (before taking study medications and
on day 2, if possible). At each time point at which stool
samples are collected, one kit of each test is used and
the actual day documented. The stool sampling devices
ensure collection of defined volumes of stool which are
given to a buffer that hinders degradation of hemoglobin
(for example FOBGold®Tube Screen test: 10 mg stool in
1.7 ml buffer). All stool samples are collected at the par-
ticipants’ homes and prior to initiation of large bowel
preparation for colonoscopy. The stool samples are
stored in the refrigerators and sent by mail to the coord-
inating center (Heidelberg) using special pre-paid and
addressed mailing devices.
Participants’ information
To ensure adherence to the study medication, participants
are instructed in detail before start of the trial. Given that
the medication scheme includes only one single dose of
study drug, no major problems in taking the medication is
expected. All participants receive a participant diary in
Fig. 1 Overview of study flow
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which they document if and when they took the study
medication, and if and when they collected the stool sam-
ples. The participant sends this diary to the coordinating
center in Heidelberg using a prepaid envelop. Finally, par-
ticipants are asked to fill out a standardized questionnaire
addressing potential determinants of risk of colorectal
neoplasms and of test performance, including general par-
ticipant characteristics, co-morbidities, and lifestyle fac-
tors. They can either do this during their visit to the study
center or at home.
Colonoscopy
The colonoscopy is planned and conducted in the set-
ting of screening for CRC or diagnostic workup and, as
such, it is not part of the trial. However, the investigator
must ensure that there are at least 5 days (4 full acetyl-
salicylic acid-free days) between taking the study medi-
cation and the colonoscopy. Although a single dose of
acetylsalicylic acid is not considered a contraindication
for elective colonoscopy, this time interval was chosen
to minimize any possibility of an increased risk of bleed-
ing at colonoscopy or endoscopic removal of small
polyps [10–12]. However, the findings from screening
colonoscopy are collected and used in the analysis.
Colonoscopy (and histology) reports are de-identified
(i.e. any personal data is removed and the participant
number is noted) and sent from the study centers to the
coordinating center (Division of Clinical Epidemiology
and Aging Research at the German Cancer Research
Centre, Heidelberg).
Data collection and documentation in recruiting centers
For each participant in the clinical trial written informed
consent is obtained before enrollment into the trial,
which is stored by the investigator in the investigator site
file (ISF) at study centers for at least 10 years after the
end of the trial.
All participants’ data collected at the study centers are
entered into the electronic Case Report Form (eCRF) by
the study physicians and physician assistants on site.
Data collected in the eCRF includes: participant number
(available once a patient is randomized); participant’s
medical history, and data collected during physical
examination; verification of compliance with inclusion
and exclusion criteria; dates of participation in the trial,
including date of informed consent, dispensing of study
material, and date of colonoscopy; information on
whether an optional blood sample was taken; laboratory
values (thrombocytes) if available from clinical routine;
adverse events (AEs); protocol violations; date of
drop-out and reasons, if applicable.
The eCRF does not contain the participant’s identify-
ing information, but only his/her participant number.
Entries in the eCRF may only be made by the investiga-
tor or persons authorized by him. If corrections in the
eCRF are necessary, the initial entry will be kept in an
electronic log (audit-trail). A list is kept of the
Table 1 Study schedule
Trial-specific procedures Screening Baseline Treat-ment Observation Post-study
Timeline Day 0 Day 2 Day 3 Day 4 Colonoscopy from day 5 onwards
Informed consent X




Blood sampling for biomarker analyses (optional)e X
Questionnaireb X
Handing over stool collection material and subject diaryc X
Drug administration (Acetylsalicylic acid or placebo) X
Stool sampled (FOBGold®Tube Screen) X X X X
Stool sampled (FD Hb/Hp Complex) X X X X
Concomitant therapy recording X X X X
(S)AE recordingf X X X X
aAge, sex, weight, height, and blood pressure
bThe questionnaire includes questions on family history of CRC and lifestyle factors such as smoking and alcohol consumption
cEight kits are handed over
dIf stool collection on these days is not possible because of constipation or other reasons, stool collection may be postponed to the subsequent days; participants
are also allowed to collect only two stool samples, which should be at baseline (without medication) and on day 2, if possible
eBlood sampling for biomarker analysis: 2 EDTA tubes; 2 serum tubes
fInterview of participants before colonoscopy
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individuals who are authorized to make data changes. At
the end of the trial, data collected in the eCRF are trans-
ferred digitally into a database at the coordinating center
in Heidelberg.
To confirm adherence to the study medication, the
participants are asked to bring the empty package of the
study medication when coming to the planned colonos-
copy. Information on medication usage is collected in a
drug accountability log.
Data collection and documentation in the coordinating
center
The linkage between biological samples, questionnaires,
and colonoscopy results is established only by the
unique participant number. The information collected
from colonoscopy and histology reports is entered into
an additional standardized study database by trained
staff in the coordinating center, using double data entry
by two independent and blinded staff members. Data en-
tries are checked for inconsistencies through comparison
of the corresponding data sets. In case of differences in
data sets, original reports are checked for validation.
Documentation of information collected in the ques-
tionnaire and participants’ diary include automated scan-
ning of the questionnaires, optical verification of the
scans by trained staff, and comprehensive plausibility
checks prior to statistical analysis. All collected informa-
tion is stored at the coordinating center at least 10 years
after the end of the trial.
Analysis of stool samples
Laboratory analyses of immunochemical FOBGold®Tube
Screen test are performed in a blinded manner in an ex-
ternal cooperating laboratory (Limbach Laboratory,
Heidelberg). Analyses for the FD Hb/Hp Complex test
are performed at the laboratory of the Department of
Clinical Epidemiology and Aging Research at the
German Cancer research Center in Heidelberg. The FD
Hb/Hp Complex quick test enables to test human
hemoglobin (Hb) and hemoglobin/haptoglobin complex
(Hb/Hp); however, in this trial, only the results from the
Hb test will be reported. Both laboratories have extensive
experience in the analysis of iFOBTs from previous studies
of this group. The iFOBTs used in this trial are commer-
cially available, validated tests. Standard Operating Proce-
dures are established and followed for the analyses.
Analysis and storage of blood samples
Blood samples are picked up from the study centers by a
lab sample transportation service and brought to the co-
ordinating center in Heidelberg. Blood samples are
stored at the coordinating center at − 80 °C without a
time limit for future development and analysis of bio-
markers including genetic markers potentially related to
the presence of advanced adenomas and/or colorectal
carcinoma and for analysis of the determinants of the ef-
fects of acetylsalicylic acid.
As intensive research into new blood tests is continu-
ously ongoing, it is neither meaningful nor possible to
explicitly state which exact markers will be tested in the
future. Long-term storage of the blood samples collected
in this trial will enable timely validation of emerging
promising early detection markers in the years to come.
Only the staff of the coordinating center will have ac-
cess to the samples. However, the samples may be trans-
ported to laboratories of cooperating partners (including
international partners) for specific analyses.
All laboratory analyses are done in a blinded fashion
with respect to both treatment given and clinical/colon-
oscopy data.
Quality assurance
The study medication (both acetylsalicylic acid and pla-
cebo) is packaged, labeled and blinded according to ap-
plicable GCP-V and GMP rules by the Pharmacy of the
University Hospital Heidelberg, holding a manufacturing
authorization.
There is a responsible investigator in every recruiting
study center. The responsible investigator has completed
a certified investigator training, including training in
ICH-GCP, GCP-V, and AMG (German drug law). The
responsible investigator of a study center keeps a confi-
dential list with full names and dates of birth of all par-
ticipants in the trial, giving reference to the participant’s
records. This list is kept in the investigator site file at
the study centers. For enrolled participants the date of
enrolment and the allocation/randomization number is
recorded in this list. The identity of the participants will
not be revealed to unauthorized persons.
The participating study centers are visited on a regular
basis by qualified staff (visits include an initiation visit, a
number of interim visits during the recruitment phase
(on-site-monitoring), and a close-out visit). A report is
written after each visit.
The steering committee (consisting of the head of the
coordinating center, the clinical pharmacology consult-
ant, and the principal investigator of the study (LKP))
meets regularly, either in person or via a telephone con-
ference, to discuss study progress, monitoring reports,
and any study-related problems. The conclusions of
these meetings are documented.
Safety assessment
Participants are asked about concurrent use of medica-
tion and diseases at inclusion to minimize the risk of
AEs. Candidate participants in the trial are excluded if
they use potentially interacting medications or have ill-
nesses that may be worsened by participation in this
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trial. In the patient information documents, participants
are informed about all relevant potential AEs that may
occur. Furthermore, participants are instructed to con-
tact their general practitioner or the investigator in the
unlikely case of a severe medical problem.
The observation period for AEs is defined as day 0 to
day 4 for this trial. When the participants come for the
scheduled study-independent colonoscopy, they are
asked about any potential AEs or events potentially re-
lated to the use of the medication. All AEs are docu-
mented and the investigator judges intensity,
seriousness, and relatedness of an AE using standard cri-
teria. This information is documented in a standardized
way in the eCRF. All serious AEs (SAEs) must be re-
ported within 24 h, or on the next working day at the
latest, using a standardized SAE report form.
Methods against bias
The trial is randomized to account for potential confound-
ing factors. Block randomization is used by randomizing
participants within blocks such that an equal number is
assigned to each treatment (the order in which treatments
are allocated in each block is random). Randomization list
is compiled with the randomization software RITA –
Randomisation in Treatment Arms, Version 1.24, it.e.c.x.
All laboratory tests as well as extraction of clinical data
from colonoscopy and pathology reports are done in a
blinded manner to avoid information bias. Data extrac-
tion and data entry (where applicable) is done by two in-
dependent and blinded reviewers. Discrepant coding is
resolved according to standard operating procedures to
achieve the maximum accuracy possible. In addition, the
study centers as well as all participants receive detailed
instructions to ensure uniform collection and handling
of stool and blood samples. Pre-analysis conditions, in-
cluding data on storage conditions and duration and
mode of transportation, are also documented in detail to
control for potential variation.
Sample size calculation
The sample size is estimated based on the results of the
preliminary study including participants from CRC
screening with self-reported acetylsalicylic acid use [7].
Accounting for an expected loss of data of about 20%
and with an expected prevalence of advanced neoplasms
of 10%, 100 advanced neoplasms are expected in each of
the two groups. Assuming a sensitivity of 36% in the pla-
cebo group (as in our preliminary study) and applying
2-sided chi-square tests with continuity correction at an
alpha level of 0.05, this trial should have a power of 90%
to detect an increase in sensitivity by short term use of
low-dose acetylsalicylic acid to 60% in the entire trial
population, and a power of 90% to detect an increase in
sensitivity to 70% in gender-specific analyses (sensitivity
was 71% in our preliminary study [7]). Furthermore, spe-
cificity will be estimated at high levels of precision in
both groups, with an expected confidence interval ran-
ging from 88 to 92% for a specificity of 90%.
Statistical analysis
Standard techniques for the analysis of diagnostic tests will
be used [13, 14]. Diagnostic accuracy of the two iFOBTs at
the different time points of stool collection will be quanti-
fied by estimating sensitivity, specificity, likelihood ratios,
positive and negative predictive values (and corresponding
95% confidence intervals) at cut points yielding levels of
specificity typically required for routine testing of
average-risk populations (> 90%), using the results of col-
onoscopy as the gold standard. These results will be com-
pared between participants randomized to receive
acetylsalicylic acid and those randomized to receive pla-
cebo in an intention-to-treat analysis. For the primary
endpoint, sensitivity for predefined (test-specific) cut
points of test positivity of the FOBGold®Tube Screen test
will be compared between users and non-users of acetyl-
salicylic acid. The stool samples taken on day 2 will be
used for these primary analyses.
In addition, the tests will be evaluated over the whole
range of cut points by ROC curve analyses and the area
under the ROC curve (AUC) will be determined. All
analyses will be performed for the total trial population,
as well as stratified for gender and separately for the dif-
ferent colonoscopy results (advanced adenomas, defined
as presence of at least 1 adenoma with at least 1 of the
following features: ⩾1 cm in size, tubulovillous or villous
components, high-grade dysplasia, and carcinomas).
Analyses will be carried out for stool tests taken at base-
line before commencing the study medication and on
different days after a single dose of the study drug. Fur-
thermore, analyses will be carried out in which results of
tests from stool samples taken on multiple (2 or 3) dif-
ferent days are combined to assess the gain in diagnostic
performance by test application on multiple days. Diag-
nostic performance and its enhancement by acetylsali-
cylic acid will be evaluated and compared for both of the
two iFOBTs employed.
Safety analyses will be performed in the total trial popu-
lation (i.e. all randomized patients, independent from the
availability of stool samples or colonoscopy reports).
The primary endpoints will be analyzed with confirma-
tory aim; the other statistical analyses will be exploratory.
Discussion
In this trial we aim to evaluate the diagnostic perform-
ance of two iFOBTs for detecting advanced colorectal
neoplasms after a single dose of acetylsalicylic acid as
compared to placebo. Additionally, gender-specific
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performance of the tests and gain in diagnostic perform-
ance by test application on multiple days will be
evaluated.
Choice of acetylsalicylic acid dose
Most participants in our previous study [7] used acetyl-
salicylic acid in a dose of 100 mg per day. This dosing
scheme leads to predictable suppression of platelet func-
tion after repeated administration. However, the onset of
effects is slow and maximal suppression is achieved only
after about 5 days [15]. Therefore, a loading dose of
500 mg is given in clinical routine when a rapid onset of
thrombocyte inhibition is required. Based on published
data, a dose of 300 mg seems to be similarly effective
[16, 17]. However, an enteric-coated preparation of the
same dose was associated with submaximal inhibition
[17] and is therefore not used in our trial.
Benefit/ risk assessment
Acetylsalicylic acid is a very well-known and
well-characterized drug that has been on the market for
more than 100 years (since 1899). Only one dose is given
in this trail and this dose (300 mg) is lower than the nor-
mal adult dose required for pain relief (500 mg) and is
usually classified as “low-dose”. As such it is approved
for the secondary prevention of myocardial infarction
(where doses from 75 to 325 mg are used). Furthermore,
patients with risk factors (e.g. bleeding diathesis) are ex-
cluded. Thus, the occurrence of serious adverse reac-
tions is considered very unlikely.
Previous studies analyzing the association between
acetylsalicylic acid use and the performance of FOBTs ad-
dressed the potentially hampered specificity due to an in-
creased risk of bleeding from insignificant colonic lesions
or from upper gastrointestinal blood loss [18–22]. How-
ever, these studies mostly used guaiac-based FOBTs, which
are more likely to detect upper gastrointestinal blood, as
they respond to the pseudoperoxidase activity of the heme
moiety of hemoglobin, which remains quite stable
throughout the gastrointestinal tract, whereas the iFOBTs
respond to the globin moiety, which is degraded in the
gastrointestinal tract [7, 18–21]. A recent observational
study on acetylsalicylic acid use and iFOBT performance
showed a trend towards an increase in sensitivity (from
51.2 to 66.7%) without loss of specificity in acetylsalicylic
acid or NSAID users, but the difference did not reach stat-
istical significance, likely due to a relatively low number of
acetylsalicylic acid/NSAID users [20].
Although these results are intriguing, further work is
needed for translation of these findings into routine
practice of CRC screening. In particular, low-dose acetyl-
salicylic acid was used chronically for cardiovascular pre-
vention in most cases and by a relatively small subgroup
of participants (approximately 10%) in our previous
observational study [7]. Although knowledge on
pharmacokinetics and pharmacodynamics of acetylsali-
cylic acid suggests similar effects of a single dose of
acetylsalicylic acid (as might be considered for CRC
screening) irrespective of cardiovascular risk, this sug-
gestion should be empirically tested in a double-blind
placebo-controlled clinical trial, whose design we report
here. Furthermore, most users of low-dose acetylsalicylic
acid in our previous study were men and data were in-
sufficient to evaluate diagnostic performance among
women. Also, our previous study did not allow the as-
sessment of potential further improvement by stool test-
ing on multiple days rather than on a single day.
Impact
The participants in this trial have no indication for
acetylsalicylic acid and no individual benefit from taking
one dose of acetylsalicylic acid. However, should this
trial show that one dose of acetylsalicylic acid strongly
increases the sensitivity of the iFOBTs without relevant
loss in specificity, these findings may improve diagnostic
procedures in future patients, which might affect also
trial patients if repeated screening is required.
To the best of our knowledge, there has been no previ-
ous controlled clinical trial investigating the increase in
diagnostic accuracy of iFOBTs with acetylsalicylic acid
intake in a large target population for CRC screening,
i.e. (largely) asymptomatic women and men at average
risk of CRC. If the findings from our previous observa-
tional study [7] are confirmed in this trial, this interven-
tion would considerably improve the diagnostic accuracy
of iFOBTs and thus lead to enhanced early detection of
colorectal neoplasms. Thus, the results of this trial may
have a large public health impact.
Appendix
Full list of inclusion and exclusion criteria
Inclusion criteria
 Age 40 to 80 years (both males and females;
premenopausal women must have a negative
pregnancy test before inclusion into the trial,
postmenopausal women are defined as women who
have not had menstrual bleeding for at least
12 months, or have been surgically sterilized)
 Planned screening or diagnostic colonoscopy
 Able to speak and understand German sufficiently to
be able to give written informed consent and
comply with the trial requirements
Exclusion criteria
 Factors potentially influencing the primary endpoint
 Diseases/symptoms
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 Chronic inflammatory bowel disease (e.g.
Crohn’s disease, ulcerative colitis)
 Colonoscopy due to positive fecal occult blood test
 History of colorectal cancer
 Angiodysplasia of the colon
 Anamnestic or observed blood loss per anum
 Use of any of the following drugs
 Within 2 weeks before the trial
 Anticoagulants (including, but not limited
to heparin, vitamin K antagonists [e.g.
phenprocoumon, warfarin], direct thrombin
inhibitors [e.g. dabigatran], or factor Xa
inhibitors [e.g. apixaban, rivaroxaban])
 Antiplatelet drugs (e.g. clopidogrel,
prasugrel, ticlopidine)
 Within 1 week before the trial
 Acetylsalicylic acid
 Within 3 days before the trial
 NSAIDs including selective COX-2 inhibitors
 Factors potentially affecting the safety
 Any current clinically relevant signs and
symptoms, including
 Signs and symptoms suggesting acute peptic
ulcer disease
 Known clinically relevant thrombocytopenia
 Acute infection
 Volume deficit (dehydration)
 Any currently present allergy with dermal
reactions, pruritus, or urticaria
 Severe or insufficiently controlled asthma
 Severe kidney or liver diseases (e.g. GFR <
30 ml/min, liver cirrhosis)
 Severe, not sufficiently treated heart failure (as
judged by the investigator)
 Severe, poorly controlled arterial hypertension
 Any other unclear symptoms needing further
investigation in the opinion of the investigator
 Any of the following anamnestic findings
 History of severe gastrointestinal bleeding
 Known hemorrhagic diathesis, including, but
not limited to, hypoprothrombinemia, severe
thrombocytopenia, hemophilia
 Asthma, except for patients who have used
acetylsalicylic acid in the past without negative
effects
 Hypersensitivity against salicylic acid or other
ingredients of the study drugs
 Previous intolerance to NSAIDs including
selective COX-2 inhibitors, or antirheumatic
medications
 Severe gout (e.g. recurrent attacks)
 Hereditary oxaluria
 Known G6PD or glutathione peroxidase
deficiency
 Known epilepsy with generalized seizures
 Severe cardiac diseases (including, but not
limited to, myocardial infarction in the past
6 months)




 NSAIDs including selective COX-2 inhibitors
 Methotrexate ≥15 mg/week
 Systemically administered glucocorticoids
 Selective serotonin reuptake inhibitors (SSRIs)
 Valproic acid
 Planned surgery/dental treatment during
participation in the trial
 Other factors
 Known or suspected relevant alcohol abuse
 Known or suspected illicit drug abuse
 Pregnancy
 Suspected non-compliance with the trial
procedures
 Participation in another clinical trial
Additional file
Additional file 1: List of Ethics Committees who were involved in
approval of the trial. (DOCX 20 kb)
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